|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Alcoholism | |||||
| 2 | More general conditions related to this trial | ||||
| Alcohol-Related Disorders | |||||
| Disorders of Environmental Origin | |||||
| Mental Disorders | |||||
| Substance-Related Disorders | |||||
| 3 | Interventions listed in this trial | ||||
| naltrexone (Revia) | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Naltrexone | |||||
| 5 | More general drug interventions related to this trial | ||||
| Central Nervous System Agents | |||||
| Narcotic Antagonists | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sensory System Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | |||||